title: Efficacy and safety of denosumab for the treatment of osteoporosis: A systematic review.
abstract: Denosumab is an anti-RANK ligand (RANKL) monoclonal antibody approved for the treatment of postmenopausal osteoporosis and prevention of skeletal metastasis complications. Administered subcutaneously every 6 months, it reduces the risk of vertebral fracture by 70% and of hip fracture by 40%. Its safety profile is acceptable. Denosumab may be used to treat patients with moderate to severe renal insufficiency. It has anti-fracture activity equivalent to that of zoledronic acid, but no residual effect, and no action at all beyond 6 months. In France, denosumab is reimbursed as a second-line treatment after a first attempt with bisphosphonate.
authors.affiliation: Department of Endocrinology, Lorraine University, University Hospital Center of Nancy, Vandœuvre-lès-Nancy, France; Department of Internal Medicine II, Cheikh Anta Diop University, University Hospital Center of Dakar, Dakar, Senegal.
authors.forename: Demba
authors.initials: D
authors.lastname: Diédhiou
authors.affiliation: Department of Endocrinology, Lorraine University, University Hospital Center of Nancy, Vandœuvre-lès-Nancy, France.
authors.forename: Thomas
authors.initials: T
authors.lastname: Cuny
authors.affiliation: Department of Internal Medicine II, Cheikh Anta Diop University, University Hospital Center of Dakar, Dakar, Senegal.
authors.forename: Anna
authors.initials: A
authors.lastname: Sarr
authors.affiliation: Department of Internal Medicine II, Cheikh Anta Diop University, University Hospital Center of Dakar, Dakar, Senegal.
authors.forename: Saïd
authors.initials: S
authors.lastname: Norou Diop
authors.affiliation: Department of Endocrinology, Lorraine University, University Hospital Center of Nancy, Vandœuvre-lès-Nancy, France.
authors.forename: Marc
authors.initials: M
authors.lastname: Klein
authors.affiliation: Department of Endocrinology, Lorraine University, University Hospital Center of Nancy, Vandœuvre-lès-Nancy, France. Electronic address: g.weryha@chu-nancy.fr.
authors.forename: Georges
authors.initials: G
authors.lastname: Weryha
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D016723:Bone Remodeling / Q000187:drug effects; D000069448:Denosumab / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004164:Diphosphonates / Q000627:therapeutic use; D005260:Female; D005602:France; D006620:Hip Fractures / Q000517:prevention & control; D006801:Humans; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy*; D016103:Spinal Fractures / Q000517:prevention & control
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D000069448:Denosumab
keywords: Denosumab; Fracture risk; Insuffisance rénale; Osteoporosis; Ostéoporose; Renal insufficiency; Risque fracturaire; Safety; Tolérance